PROC clinical trials at UCLA

1 in progress, 0 open to eligible people

Showing trials for

  • HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors

    Sorry, not currently recruiting here

    HWK-007-101 is a multicenter, open-label, first-in-human (FIH) Phase 1 study evaluating HWK-007, a protein tyrosine kinase 7 (PTK7)-targeted antibody drug conjugate (ADC), in adult participants with advanced or metastatic solid tumors known to be expressing PTK7. The study employs a sequential dose escalation and dose expansion design without a control group.

    Los Angeles, California and other locations

Our lead scientists for PROC research studies include .

Last updated: